BVF Partners ETNB Position
Exited10-Fund ConvergenceBVF Partners exited their position in 89bio Inc. (ETNB) in Q1 2025, after holding the stock for 9 quarters.
The position was first reported in Q1 2023 and has been tracked across 9 quarterly 13F filings.
ETNB is a convergence signal: 10 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Pegozafermin in 808 days (Jun 30, 2028), making the timing of BVF's position particularly relevant.
About 89bio Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Full company profile →BVF Partners ETNB Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q1 2025 | Exited | 0 | -4,333,885 | $0 |
| Q4 2024 | Decreased | 4,333,885 | -2,477,746 | $33.9M |
| Q3 2024 | Decreased | 6,811,631 | -756,848 | $50.4M |
| Q2 2024 | Increased | 7,568,479 | +3,521,125 | $60.6M |
| Q1 2024 | Held | 4,047,354 | — | $47.1M |
| Q4 2023 | Increased | 4,047,354 | +2,201,200 | $45.2M |
| Q3 2023 | Held | 1,846,154 | — | $28.5M |
| Q2 2023 | Held | 1,846,154 | — | $35.0M |
| Q1 2023 | New | 1,846,154 | +1,846,154 | $28.1M |
Frequently Asked Questions
Does BVF Partners own ETNB?
No. BVF Partners exited their position in 89bio Inc. (ETNB) in Q1 2025. They previously held the stock for 9 quarters.
How many hedge funds own ETNB?
10 specialist biotech hedge funds currently hold ETNB, including RA Capital Management, Deep Track Capital, Avoro Capital Advisors and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did BVF Partners first buy ETNB?
BVF Partners's position in ETNB was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is BVF Partners's ETNB position increasing or decreasing?
BVF Partners completely exited their ETNB position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ETNBCompany Page →
All fund holders, insider trades, catalysts, and cash runway
BVF PartnersPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →